A phase 2, multicenter, open‐label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 643-650

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma

By Lafuma A.   Dreno B.   Delaunay M.   Emery C.   Fagnani F.   Hieke K.   Bonerandi J.-J.   Grob J.-J.   for the French Cooperative Group on Melanoma  

European Journal of Cancer, Vol. 37, Iss. 3, 2001-02 ,pp. : 369-375

Elsevier

Access to resources Recommend Favorite

Fotemustine and Dacarbazine Plus Recombinant Interferon Alpha2a in the Treatment of Advanced Melanoma

By Comella P.   Daponte A.   Casaretti R.   Ionna F.   Fiore F.   Presutti F.   Frasci G.   Caponigro F.   Gravina A.   Parziale A.P.   Mozzillo N.   Comella G.  

European Journal of Cancer, Vol. 33, Iss. 8, 1997-07 ,pp. : 1326-1329

Elsevier

Access to resources Recommend Favorite

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

By Khammari Amir   Nguyen Jean-Michel   Pandolfino Marie   Quereux Gaëlle   Brocard Anabelle   Bercegeay Sylvain   Cassidanius Alain   Lemarre Philippe   Volteau Christelle   Labarrière Nathalie   Jotereau Francine   Dréno Brigitte  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 11, 2007-11 ,pp. : 1853-1860

Springer Publishing Company

Access to resources Recommend Favorite

Dacarbazine, Vincristine, Bleomycin and Lomustine plus Natural Interferon-alpha for Metastatic Melanoma

By Reinhold U.   Bruske T.   Kreysel H.W.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 180-180

Elsevier

Access to resources Recommend Favorite